Drug intelligence / Profile preview

NTP0127B

Development stage: Preclinical
Lead developer: Trinity College Dublin

Overview

NTP0127B is a natural plant extract derived from Irish bogland species, developed as part of the "Unlocking Nature’s Pharmacy from Bogland Species" project at Trinity College Dublin's NatPro Centre. It is being investigated for its immunomodulatory potential in the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis, and irritable bowel syndrome (IBS). In ex vivo colonic tissue explant models, NTP0127B has demonstrated the ability to modulate immune-metabolic profiles, specifically reducing the secretion of the anti-inflammatory cytokine IL-10 in tissues from IBS patients.

Targets

IL10 (Interleukin-10)

Beyond the preview

Go deeper on NTP0127B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NTP0127B.

Explore the full profile